<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1704233555
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SYMBICORT TURBUHALER
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BUDESONIDE,FORMTEROL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        160,4.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        169.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        R03AK07
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Symbicort Turbuhaler is an inhaler that is used to treat asthma in adults and adolescents aged 12 &ndash; 17&nbsp;years. It is also used to treat the symptoms of Chronic Obstructive Pulmonary Disease (COPD) in adults aged 18&nbsp;years and older. It contains two different medicines: budesonide and formoterol fumarate dihydrate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Budesonide belongs to a group of medicines called &lsquo;corticosteroids&rsquo;. It works by reducing and preventing swelling and inflammation in your lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Formoterol fumarate dihydrate belongs to a group of medicines called &lsquo;long-acting beta<sub>2</sub> adrenoceptor agonists&rsquo; or &lsquo;bronchodilators&rsquo;. It works by relaxing the muscles in your airways. This helps you to breathe more easily.</p><p>&nbsp;</p><p><strong>Asthma</strong></p><p>Symbicort Turbuhaler can be prescribed for asthma in two different ways.</p><p>&nbsp;</p><p><strong>Some people are prescribed Symbicort Turbuhaler and a separate reliever inhaler</strong></p><p><strong>a)&nbsp; </strong><strong>Symbicort Turbuhaler every day and a separate reliever inhaler when required.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You take a fixed dose of Symbicort Turbuhaler every day. This helps to prevent asthma symptoms from happening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You use a separate reliever inhaler when you get asthma symptoms, to make it easier to breathe again.</p><p>&nbsp;</p><p><strong>Some people are prescribed Symbicort Turbuhaler as their only asthma inhaler</strong></p><p><strong>b)&nbsp; Symbicort Turbuhaler every day and also when required (Symbicort maintenance and reliever therapy).</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You take Symbicort Turbuhaler every day. This helps to prevent asthma symptoms from happening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You also take Symbicort Turbuhaler when you need extra doses for the relief of asthma symptoms, to make it easier to breathe again. You do not need a separate reliever inhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If agreed with your doctor you can also take Symbicort Turbuhaler to prevent asthma symptoms from happening for example, when exercising or on exposure to allergens.</p><p><strong>&nbsp;</strong></p><p><strong>Chronic obstructive pulmonary disease (COPD)</strong></p><p>Symbicort Turbuhaler can also be used to treat the symptoms of COPD in adults. COPD is a long-term disease of the airways in the lungs, which is often caused by cigarette smoking.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Symbicort Turbuhaler:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to budesonide, formoterol, or the other ingredient of this medicine (listed in section&nbsp;6), which is lactose (which contains small amounts of milk protein).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your healthcare practitioner before using Symbicort Turbuhaler if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are diabetic.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a lung infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have high blood pressure or you have ever had a heart problem (including an uneven heartbeat, a very fast pulse, narrowing of the arteries or heart failure).</p><p><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>You have problems with your thyroid or adrenal glands.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have low levels of potassium in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe liver problems.</p><p>Contact your doctor if you experience blurred vision or other visual disturbances.</p><p>&nbsp;</p><p><strong>Other medicines and Symbicort Turbuhaler</strong></p><p>Tell your healthcare practitioner if you are using, have recently used or might use any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are using any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blocker medicines (such as atenolol or propranolol for high blood pressure), including eyedrops (such as timolol for glaucoma).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for a fast or uneven heart beat (such as quinidine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines like digoxin, often used to treat heart failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics, also known as &lsquo;water tablets&rsquo; (such as furosemide). These are used to treat high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steroid medicines that you take by mouth (such as prednisolone).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Xanthine medicines (such as theophylline or aminophylline). These are often used to treat asthma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other bronchodilators (such as salbutamol).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tricyclic anti-depressants (such as amitriptyline) and the anti-depressant nefazodone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenothiazine medicines (such as chlorpromazine and prochlorperazine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines called &lsquo;HIV-protease inhibitors&rsquo; (such as ritonavir) to treat HIV infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to treat infections (such as ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin and telithromycin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for Parkinson&rsquo;s disease (such as leva-dopa).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for thyroid problems (such as levo‑thyroxine).&nbsp;</p><p>&nbsp;</p><p>If any of the above applies to you, or if you are not sure, talk to your doctor or pharmacist before using Symbicort Turbuhaler.</p><p>&nbsp;</p><p>Also tell your healthcare practitioner if you are going to have a general anaesthetic for an operation or for dental work.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant, or planning to get pregnant, talk to your healthcare practitioner before using Symbicort Turbuhaler - do not use Symbicort Turbuhaler unless your doctor tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get pregnant while using Symbicort Turbuhaler, do not stop using Symbicort Turbuhaler but talk to your doctor immediately.</p><p><s>&middot;&nbsp;</s>If you are breast-feeding, talk to your healthcare practitioner before using Symbicort Turbuhaler.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Symbicort Turbuhaler has no or negligible effect on your ability to drive or to use tools or machines.</p><p><strong>Symbicort Turbuhaler contains lactose</strong></p><p>Symbicort Turbuhaler contains lactose, which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before using this medicine. The amount of lactose in this medicine does not normally cause problems in people who are lactose intolerant.</p><p>The excipient lactose contains small amounts of milk proteins, which may cause an allergic reaction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use this medicine exactly as your doctor has told you. Check with your healthcare practitioner if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been prescribed a daily dose of Symbicort Turbuhaler, it is important to use your inhaler every day, even if you have no asthma or COPD symptoms at the time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are using Symbicort Turbuhaler for asthma, your doctor will want to regularly check your symptoms.</p><p>If you have been taking steroid tablets for your asthma or COPD, your doctor may reduce the number of tablets that you take, once you start to use Symbicort Turbuhaler. If you have been taking oral steroid tablets for a long time, your doctor may want you to have blood tests from time to time. When reducing oral steroid tablets, you may feel generally unwell even though your chest symptoms may be improving. You might experience symptoms such as a stuffy or runny nose, weakness or joint or muscle pain and rash (eczema). If any of these symptoms bother you, or if symptoms such as headache, tiredness, nausea (feeling sick) or vomiting (being sick) occur, please contact your doctor immediately. You may need to take other medication if you develop allergic or arthritic symptoms. You should speak to your doctor if you are concerned as to whether you should continue to use Symbicort Turbuhaler.</p><p>Your doctor may consider adding steroid tablets to your usual treatment during periods of stress (for example, when you have a chest infection or before an operation).</p><p><strong>Important information about your asthma or COPD symptoms:</strong></p><p>If you feel you are getting breathless or wheezy while using Symbicort Turbuhaler, you should continue to use Symbicort Turbuhaler but go to see your doctor as soon as possible, as you may need additional treatment.</p><p>Contact your doctor immediately if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your breathing is getting worse or you often wake up at night with asthma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your chest starts to feel tight in the morning or your chest tightness lasts longer than usual.</p><p>These signs could mean that your asthma or COPD is not being properly controlled and you may need different or additional treatment immediately.</p><p>&nbsp;</p><p><strong>Asthma:</strong></p><p>Symbicort Turbuhaler can be prescribed for asthma in different ways. The amount of Symbicort Turbuhaler to use and when to use it depends on how it has been prescribed for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been prescribed a fixed dose of Symbicort Turbuhaler and a separate reliever inhaler, read the section called &lsquo;a) Using Symbicort Turbuhaler and a separate reliever inhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been prescribed Symbicort Turbuhaler as your only inhaler, read the sections called &lsquo;b) Using Symbicort Turbuhaler as your only asthma inhaler every.</p><p><strong>&nbsp;</strong></p><p><strong>a) Using Symbicort Turbuhaler and a separate reliever inhaler </strong></p><p><strong>Take your fixed dose of Symbicort Turbuhaler every day. </strong>This helps to prevent asthma symptoms from happening.</p><p><strong>&nbsp;</strong></p><p><strong>Adults (18&nbsp;years and above)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 1 or 2&nbsp;inhalations, twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may increase this to 4&nbsp;inhalations, twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your symptoms are well controlled, your doctor may ask you to take your medicine once a day.</p><p>&nbsp;</p><p><strong>Adolescents (12 to 17&nbsp;years)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 1 or 2&nbsp;inhalations, twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your symptoms are well controlled, your doctor may ask you to take your medicine once a day.</p><p>A lower strength of Symbicort Turbuhaler is available for children aged from 6 to 11&nbsp;years.</p><p>Symbicort Turbuhaler is not recommended to be used in children who are younger than 6&nbsp;years.</p><p>Your doctor (or asthma nurse) will help you to manage your asthma. They will adjust the dose of this medicine to the lowest dose that controls your asthma. However, do not adjust or stop the dose without talking to your doctor (or asthma nurse) first.</p><p><strong>Use a separate reliever inhaler to treat asthma symptoms when they happen.</strong> Always keep your reliever inhaler with you to use when you need it. Do not use Symbicort Turbuhaler to treat asthma symptoms - use your reliever inhaler.</p><p>&nbsp;</p><p><strong>b) Using Symbicort Turbuhaler every day and also when required (Symbicort maintenance and reliever therapy)</strong></p><p>Only use Symbicort Turbuhaler in this way if your doctor has told you to and if you are aged 12 or above.</p><p>&nbsp;</p><p><strong>Use your Symbicort Turbuhaler every day. </strong>This helps to prevent asthma symptoms from happening. You can take:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;inhalation in the morning <strong>and</strong> 1&nbsp;inhalation in the evening</p><p><strong>or</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;inhalations in the morning</p><p><strong>or</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;inhalations in the evening.</p><p>Your doctor may increase this to 2&nbsp;inhalations twice a day.</p><p><strong>&nbsp;Also use Symbicort Turbuhaler as your reliever inhaler </strong>to treat asthma symptoms when they happen and, if agreed with your doctor, to prevent asthma symptoms from happening (for example, when exercising or on exposure to allergens).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get asthma symptoms, take 1&nbsp;inhalation and wait a few minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not feel better, take another inhalation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take more than 6&nbsp;inhalations at a single time.</p><p>Always keep your Symbicort Turbuhaler with you, so you can use it as your reliever inhaler when you need it.</p><p><strong>Seek urgent medical advice if Symbicort Turbuhaler does not relieve your asthma symptoms or if your asthma symptoms worsen despite treatment with Symbicort.</strong></p><p>A total daily dose of more than 8&nbsp;inhalations is not normally needed. However, your doctor may allow you to take up to 12 inhalations a day for a limited period.</p><p>If you regularly need to use 8 or more inhalations a day, make an appointment to see your doctor or nurse as soon as possible. They may need to change your treatment.</p><p>Do not use more than 12&nbsp;inhalations in total in 24&nbsp;hours.</p><p><strong>Chronic Obstructive Pulmonary Disease (COPD)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only to be used by adults (aged 18&nbsp;years and above).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 2&nbsp;inhalations twice a day.&nbsp;</p><p>Your doctor may also prescribe other bronchodilator drugs, for example anticholinergics (such as tiotropium or ipratropium bromide) for your COPD disease.</p><p><strong>Preparing your new Symbicort Turbuhaler</strong></p><p>Before using your <strong>new</strong> Symbicort Turbuhaler <strong>for the first time</strong>, you need to prepare it for use as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unscrew the cover and lift it off. You may hear a rattling sound.</p><p><img alt="" width="133" height="131" src="data:image/png;base64,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" /></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold your Symbicort Turbuhaler upright with the red grip at the bottom.</p><p>.&nbsp; &nbsp; &nbsp; Turn the red grip as far as it will go in one direction. Then turn it as far as it will go in the other direction (it does not matter which way you turn it first). you&nbsp;should hear a click sound. It does not matter whether the click comes on the first or the second twist.</p><p><img alt="" width="141" height="140" src="data:image/png;base64,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" /></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do this again, turning the red grip in both directions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your Symbicort Turbuhaler is now loaded and ready for use.</p><p><strong>How to take an inhalation:</strong><br />Every time you need to take an inhalation, follow the instructions below.<br />1. Unscrew the cover and lift it off. You may hear a rattling sound.<br />2. <strong>Hold your Symbicort Turbuhaler Inhaler upright</strong> with the red grip at the bottom.</p><p><img alt="" width="133" height="131" src="data:image/png;base64,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" /></p><p>3. Do not hold the mouthpiece when you load your Symbicort Turbuhaler Inhaler. To load your Symbicort Turbuhaler Inhaler with a dose, turn the red grip as far as it will go in one direction.</p><p><img alt="" width="141" height="140" src="data:image/png;base64,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" /></p><p>Then turn it as far as it will go in the other direction (it does not matter which way you turn it first). You should hear a click sound. Your Symbicort Turbuhaler Inhaler is now loaded and ready to use. Only load your Symbicort Turbuhaler Inhaler when you need to use it.</p><p>4. <strong>Hold your Symbicort Turbuhaler Inhaler away from your mouth. Breathe out gently</strong> (as far as is comfortable). Do not breathe out through your Symbicort Turbuhaler Inhaler.<br />5. Place the mouthpiece gently between your teeth. Close your lips. Breathe in as deeply and as hard as you can through your mouth. Do not chew or bite on the<br />mouthpiece.</p><p><img alt="" width="161" height="150" src="data:image/png;base64,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" /></p><p>6. Remove your Symbicort Turbuhaler Inhaler from your mouth. Then breathe out gently. The amount of medicine that is inhaled is very small. This means you may not be able to taste it after inhalation. If you have followed the instructions, you can still be confident that you have inhaled the dose and the medicine is now in your lungs.<br />7. If you are to take a second inhalation, repeat steps 2 to 6.<br />8. Replace the cover tightly after use.</p><p><img alt="" width="164" height="141" src="data:image/png;base64,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" /></p><p>9. Rinse your mouth with water after your daily morning and/or evening doses, and spit it out.<br />Do not try to remove or twist the mouthpiece. It is fixed to your Symbicort Turbuhaler&nbsp;and must not be taken off. Do not use your Symbicort Turbuhaler&nbsp;if it has been damaged or if the mouthpiece has come apart from your Symbicort Turbuhaler.<br />As with all inhalers, caregivers should ensure that children prescribed Symbicort Turbuhaler use correct inhalation technique, as described above.<br /><strong>Cleaning your Symbicort Turbuhaler Inhaler:</strong><br />Wipe the outside of the mouthpiece once a week with a dry tissue. Do not use water or liquids.<br /><strong>When to start using a new inhaler</strong><br />The dose indicator tells you how many doses (inhalations) are left in your Symbicort Turbuhaler,&nbsp;starting with either 60 or 120 doses when it is full.</p><p><img alt="" width="193" height="141" src="data:image/png;base64,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" /></p><p>&bull; The dose indicator is marked in intervals of 10 doses. Therefore it does not show every dose.<br />&bull; When you first see a red mark at the edge of the indicator window, there are approximately 20 doses left. For the last 10 doses, the background of the dose indicator is red. When the &lsquo;0&rsquo; on the red background has reached the middle of the window, you must start using your new Symbicort Turbuhaler Inhaler.<br />Note:<br />&bull; The grip will still twist and &lsquo;click&rsquo; even when your Symbicort Turbuhaler&nbsp;is empty.<br />&bull; The sound that you hear as you shake your Symbicort Turbuhaler&nbsp;is produced by a drying agent and not the medicine. Therefore, the sound does not tell you how much medicine is left in your Symbicort Turbuhaler.<br />&bull; If you load your Symbicort Turbuhaler&nbsp;more than once by mistake before taking your dose, you will still only receive one dose. However, the dose indicator will register all the loaded doses.</p><p><strong>If you use more Symbicort Turbuhaler than you should:</strong><br />It is important that you take your dose as stated on the pharmacist&rsquo;s label or as advised by your doctor. You should not exceed your prescribed dose without seeking medical advice.<br />The most common symptoms that may occur after if you use more Symbicort Turbuhaler than you should are trembling, headache or a rapid heartbeat.</p><p><strong>If you forget to use Symbicort Turbuhaler:</strong><br />&bull; If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose.<br />&bull; Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If either of the following happen to you, stop using Symbicort Turbuhaler and talk to your doctor immediately: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of your face, particularly around your mouth (tongue and/or throat and/or difficulty swallowing) or hives together with difficulty breathing (angioedema) and/or sudden feeling of faintness. This may mean that you are having an allergic reaction. This happens rarely, affecting less than 1 in 1,000&nbsp;people.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Sudden acute wheezing or shortness of breath immediately after using your inhaler. <strong>If either of these symptoms occur, stop using your Symbicort Turbuhaler straightaway and use your &lsquo;reliever&rsquo; inhaler. Contact your doctor immediately as you may need to have your treatment changed.</strong> This happens very rarely, affecting less than 1 in 10,000&nbsp;people.</p><p>&nbsp;</p><p><strong>Other possible side effects:</strong></p><p><strong>Common (may affect up to 1 in 10&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations (awareness of your heart beating), trembling or shaking. If these effects occur, they are usually mild and usually disappear as you continue to use Symbicort Turbuhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrush (a fungal infection) in the mouth. This is less likely if you rinse your mouth out with water after using your Symbicort Turbuhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild sore throat, coughing and a hoarse voice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia (infection of the lung) in COPD patients.</p><p>Tell your doctor if you have any of the following while taking Symbicort Turbuhaler, they could be symptoms of a lung infection:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever or chills.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased mucus production, change in mucus colour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased cough or increased breathing difficulties.</p><p><strong>Uncommon (may affect up to 1 in 100&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling restless, nervous or agitated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed sleep.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heartbeat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising of the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision.</p><p><strong>Rare (may affect up to 1 in 1,000&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, itching.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bronchospasm (tightening of the muscles in the airways which causes wheezing). If the wheezing comes on suddenly after using Symbicort Turbuhaler stop using Symbicort Turbuhaler and talk to your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low levels of potassium in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uneven heartbeat.</p><p><strong>Very rare (may affect up to 1 in 10,000&nbsp;people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in behaviour, especially in children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain or tightness in the chest (angina pectoris).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in the amount of sugar (glucose) in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste changes, such as an unpleasant taste in the mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in your blood pressure.</p><p>Inhaled corticosteroids can affect the normal production of steroid hormones in your body, particularly if you use high doses for a long time. The effects include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in bone mineral density (thinning of the bones).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cataract (clouding of the lens in the eye).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glaucoma (increased pressure in the eye).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a slowing of the rate of growth of children and adolescents.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an effect on the adrenal gland (a small gland next to the kidney).</p><p>These effects are much less likely to happen with inhaled corticosteroids than with corticosteroid tablets</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not store above 30&deg;C.</p><p>Do not use the inhaler after the expiry date which is stated on the carton or on the label of your inhaler after EXP. The expiry date refers to the last day of that month</p><p>Keep the container/cap tightly closed, in order to protect from moisture.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are budesonide and formoterol fumarate dihydrate. Each inhaled dose contains 160&nbsp;micrograms of budesonide and 4.5&nbsp;micrograms of formoterol fumarate dihydrate.</p><p>The other ingredient is lactose monohydrate (which contains milk proteins).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Symbicort Turbuhaler is an inhaler containing your medicine. The inhalation powder is white in colour. Each inhaler contains either 30, 60 or 120 doses and has a white body with a red turning grip. The turning grip contains a Braille code with the number 6 for identification, to differ from other AstraZeneca inhaled products.  
Symbicort Turbuhaler is available in packs of 1 containing 120 doses.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p><strong>&nbsp;</strong>AstraZeneca AB</p><p>SE-151 85 S&ouml;dert&auml;lje</p><p>Sweden</p><p>&nbsp;</p><p><strong>Manufacturer </strong></p><p><strong>&nbsp;</strong>AstraZeneca AB</p><p>Forskargatan 18</p><p>SE-151 36 S&ouml;dert&auml;lje</p><p>Sweden</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dec 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيمبيكورت توربوهالر هو مستنشق يُستخدم لعلاج الربو لدى البالغين والمراهقين الذين تتراوح أعمارهم بين 12 و17 عامًا. كما يُستخدم لعلاج أعراض مرض الانسداد الرئوي المزمن (COPD) لدى البالغين الذين تبلغ أعمارهم 18 عامًا فأكثر. وهو يحتوي على دواءين مختلفين: بوديسونيد وفورموتيرول فومارات ثنائي الهيدرات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي بوديسونيد إلى مجموعة من الأدوية تُسمى &quot;الكورتيكوستيرويدات&quot;. وهو يعمل عن طريق تقليل التورم والالتهاب في رئتيك والوقاية منهما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي فورموتيرول فومارات ثنائي الهيدرات إلى مجموعة من الأدوية تُسمى &quot;ناهضات مستقبلات بيتا<sub>2</sub> الأدرينالية طويلة المفعول&quot; أو &quot;موسعات القصبات الهوائية&quot;. وهو يعمل عن طريق إرخاء العضلات في المسالك الهوائية. فهذا يساعدك على التنفس بمزيد من السهولة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الربو</strong></p><p dir="RTL">يمكن وصف سيمبيكورت توربوهالر لعلاج الربو بثلاث طرق مختلفة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يوصف لبعض الأشخاص سيمبيكورت توربوهالر ومستنشق مسكّن منفصل</strong></p><p dir="RTL"><strong>أ) </strong><strong>سيمبيكورت توربوهالر كل يوم ومستنشق مسكّن منفصل عند الحاجة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخذ جرعة ثابتة من سيمبيكورت توربوهالر كل يوم. وهذا يساعد على منع حدوث أعراض الربو.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تستخدم مستنشق مسكّن منفصل عندما تظهر عليك أعراض الربو، للتنفس بسهولة مرة أخرى.<strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يوصف سيمبيكورت توربوهالر لبعض الأشخاص باعتباره المستنشق الوحيد لعلاج الربو</strong></p><p dir="RTL"><strong>ب) سيمبيكورت توربوهالر كل يوم وعند الحاجة أيضًا (سيمبيكورت كعلاج مداومة وعلاج مسكّن).</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخذ سيمبيكورت توربوهالر كل يوم. هذا يساعد على منع حدوث أعراض الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما تأخذ سيمبيكورت توربوهالر عندما تحتاج إلى جرعات إضافية لتخفيف أعراض الربو، والتنفس بسهولة مرة أخرى. لا تحتاج إلى مستنشق مسكّن منفصل.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يمكنك أيضًا أخذ سيمبيكورت توربوهالر لمنع حدوث أعراض الربو، على سبيل المثال، عند ممارسة التمارين الرياضية أو عند التعرض لمسببات الحساسية، إذا تم الاتفاق مع طبيبك على ذلك.<strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>COPD = مرض الانسداد الرئوي المزمن</strong></p><p dir="RTL">يمكن أيضًا استخدام سيمبيكورت توربوهالر لعلاج أعراض مرض الانسداد الرئوي المزمن لدى البالغين. مرض الانسداد الرئوي المزمن هو مرض طويل الأمد يصيب المسالك الهوائية في الرئتين، وغالبًا ما يحدث بسبب تدخين السجائر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال سيمبيكورت توربوهالر:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه بوديسونيد أو فورموتيرول أو المكون الآخر لهذا الدواء (المذكور في القسم 6)، وهو اللاكتوز (الذي يحتوي على كميات صغيرة من بروتين الحليب).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى مقدم الرعاية الصحية قبل استخدام سيمبيكورت توربوهالر في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بعدوى في الرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ارتفاع ضغط الدم أو سبق لك أن عانيت من مشكلة في القلب (بما في ذلك عدم انتظام ضربات القلب، أو سرعة النبض، أو ضيق الشرايين، أو فشل القلب).</p><p dir="RTL"><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>كنت تعاني من مشكلات في الغدة الدرقية أو الغدد الكظرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من انخفاض مستويات البوتاسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات شديدة في الكبد.</p><p dir="RTL">اتصل بطبيبك إذا عانيت من تشوش الرؤية أو اضطرابات بصرية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسيمبيكورت توربوهالر</strong></p><p dir="RTL">أخبر مقدم الرعاية الصحية بما إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى.</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك أو الصيدلي بما إذا كنت تستخدم أيًا من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية حاصرات بيتا (مثل أتينولول أو بروبرانولول المستخدم لعلاج ارتفاع ضغط الدم)، بما في ذلك قطرات العين (مثل تيمولول المستخدم لعلاج الجلوكوما).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لتسارع أو عدم انتظام ضربات القلب (مثل كيونيدين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل ديجوكسين، وغالبًا ما تُستخدم لعلاج فشل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول، المعروفة أيضًا باسم &quot;أقراص الماء&quot; (مثل فوروسيميد). وتُستخدم لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الستيرويدية التي تتناولها عن طريق الفم (مثل بريدنيزولون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الزانثين (مثل الثيوفيلين أو الأمينوفيلين). وغالبًا ما تُستخدم لعلاج الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موسعات القصبات الهوائية الأخرى (مثل سالبوتامول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب ثلاثية الحلقة (مثل أميتريبتيلين) ونيفازودون المضاد للاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية فينوتيازين (مثل كلوربرومازين وبروكلوربيرازين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُسمى &quot;مثبطات البروتياز-HIV&quot; (مثل ريتونافير) لعلاج عدوى فيروس نقص المناعة البشرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج حالات العدوى (مثل كيتوكونازول، وإيتراكونازول، وفوريكونازول، وبوساكونازول، وكلاريتروميسين، وتيليثروميسين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض باركينسون (مثل ليفادوبا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مشكلات الغدة الدرقية (مثل ليفوثيروكسين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا)، فتحدّث إلى طبيبك، أو الصيدلي قبل استخدام سيمبيكورت توربوهالر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر مقدم الرعاية الصحية المتابع لك أيضًا بما إذا كنت ستخضع لعملية جراحية أو جراحة أسنان تتضمن تخديرًا عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والإرضاع الطبيعي والخصوبة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً، أو تخططين للحمل، فتحدثي إلى مقدم الرعاية الصحية المتابع لكِ قبل استخدام سيمبيكورت توربوهالر - لا تستخدمي سيمبيكورت توربوهالر إلا إذا طلب منكِ الطبيب ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحتِ حاملاً أثناء استخدام سيمبيكورت توربوهالر، فلا تتوقفي عن استخدامه ولكن تحدثي إلى طبيبكِ على الفور.</p><p dir="RTL"><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s>إذا كنتِ تُرضعين طفلكِ إرضاعًا طبيعيًا، فتحدثي إلى مقدم الرعاية الصحية المتابع لكِ قبل استخدام سيمبيكورت توربوهالر.</p><p dir="RTL">&nbsp;</p><p>القيادة واستخدام الآلات</p><p dir="RTL">ليس لعقار سيمبيكورت توربوهالر أي تأثير أو ربما له تأثير ضئيل على قدرتك على القيادة أو استخدام الأدوات أو الآلات.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL"><strong>يحتوي سيمبيكورت توربوهالر على اللاكتوز</strong></p><p dir="RTL">يحتوي سيمبيكورت توربوهالر على اللاكتوز، وهو نوع من السكر. إذا كان قد أخبرك طبيبك بأنك لا تتحمل بعض السكريات، فتحدث إليه قبل استخدام هذا الدواء. لا تسبب كمية اللاكتوز الموجودة في هذا الدواء عادةً مشكلات لدى الأشخاص الذين لا يتحملون اللاكتوز.</p><p dir="RTL">يحتوي لاكتوز السواغ على كميات صغيرة من بروتينات الحليب، والتي قد تسبب رد فعل تحسسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احرص دائمًا على استعمال هذا الدواء تمامًا كما أخبرك طبيبك. استشر مقدم الرعاية الصحية المتابع لك إذا لم تكن متأكدًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وُصفت لك جرعة يومية من سيمبيكورت توربوهالر، فمن المهم استخدام المستنشق كل يوم، حتى لو لم تكن تعاني من أعراض الربو أو مرض الانسداد الرئوي المزمن في ذلك الوقت.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>إذا كنت تستخدم سيمبيكورت توربوهالر لعلاج الربو، فسيرغب طبيبك في فحص الأعراض لديك بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول أقراص ستيرويد لعلاج الربو أو مرض الانسداد الرئوي المزمن، فقد يقلل طبيبك عدد الأقراص التي تتناولها، بمجرد البدء في استخدام سيمبيكورت توربوهالر. إذا كنت تتناول أقراص الستيرويد التي تؤخذ عن طريق الفم لفترة طويلة، فقد يرغب طبيبك في إجراء اختبارات دم لك من وقت لآخر. عند تقليل أقراص الستيرويد الفموية، قد تشعر بتوعك بشكل عام على الرغم من أن أعراض الصدر قد تتحسن. قد تعاني من أعراض مثل انسداد الأنف أو سيلانه، أو ضعف، أو ألم في المفاصل أو العضلات وطفح جلدي (إكزيما). إذا شعرت بالانزعاج من أي من هذه الأعراض، أو إذا حدثت أعراض مثل الصداع، أو التعب، أو الغثيان أو التقيؤ، فيُرجى الاتصال بطبيبك على الفور. قد تحتاج إلى تناول أدوية أخرى إذا ظهرت عليك أعراض حساسية أو التهاب مفصلي. يجب عليك التحدث إلى طبيبك إذا كنت قلقًا بشأن ما إذا كان يجب عليك الاستمرار في استخدام سيمبيكورت توربوهالر.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">قد يفكر طبيبك في إضافة أقراص ستيرويد إلى علاجك المعتاد خلال فترات الإجهاد (على سبيل المثال، عندما تعاني من عدوى في الصدر أو قبل إجراء عملية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول أعراض الربو أو مرض الانسداد الرئوي المزمن لديك</strong></p><p dir="RTL">إذا شعرت بأنك تعاني من ضيق في التنفس أو أزيز أثناء استخدام سيمبيكورت توربوهالر، فيجب عليك الاستمرار في استخدامه ولكن توجّه إلى طبيبك في أقرب وقت ممكن، حيث قد تكون بحاجة إلى علاج إضافي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدادت حالة التنفس سوءًا أو كنت تستيقظ كثيرًا في الليل بسبب الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدأت تشعر بضيق في صدرك في الصباح أو استمر ضيق صدرك لفترة أطول من المعتاد.</p><p dir="RTL">قد تعني هذه العلامات أن الربو أو مرض الانسداد الرئوي المزمن لديك غير خاضع للسيطرة بشكل جيد وقد تكون بحاجة إلى علاج مختلف أو إضافي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الربو</strong></p><p dir="RTL">يمكن وصف سيمبيكورت توربوهالر لعلاج الربو بطرق مختلفة. تعتمد كمية سيمبيكورت توربوهالر التي يجب استخدامها وتوقيت استخدامها على وصفة سيمبيكورت توربوهالر المقدمة لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وُصفت لك جرعة ثابتة من سيمبيكورت توربوهالر ومستنشق مسكّن منفصل، فاقرأ القسم &rsquo;أ) استخدام سيمبيكورت توربوهالر ومستننشق مسكّن منفصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وُصف لك سيمبيكورت توربوهالر باعتباره المستنشق الوحيد، فاقرأ القسمين &rsquo;ب) استخدام سيمبيكورت توربوهالر باعتباره المستنشق الوحيد المخصص للربو كل يوم&lsquo; و&rsquo;ج) استخدام سيمبيكورت توربوهالر باعتباره المستنشق الوحيد المخصص للربو فقط عند الحاجة إليه&lsquo;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ) استخدام سيمبيكورت توربوهالر ومستنشق مسكّن منفصل </strong></p><p dir="RTL"><strong>خذ جرعتك الثابتة من سيمبيكورت توربوهالر كل يوم. </strong>هذا يساعد على منع حدوث أعراض الربو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون (18 عامًا فما فوق)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي نشقة واحدة أو نشقتان، مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُزيد طبيبك الجرعة إلى 4 نشقات، مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت الأعراض التي تعاني منها خاضعة للسيطرة بشكل جيد، فقد يطلب منك طبيبك أخذ دوائك مرة واحدة يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراهقون (12 إلى 17 عامًا)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي نشقة واحدة أو نشقتان، مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت الأعراض التي تعاني منها خاضعة للسيطرة بشكل جيد، فقد يطلب منك طبيبك أخذ دوائك مرة واحدة يوميًا.</p><p dir="RTL">يتوفر سيمبيكورت توربوهالر بتركيز أقل للأطفال الذين تتراوح أعمارهم بين 6 و11 عامًا.</p><p dir="RTL">لا يوصى باستخدام سيمبيكورت توربوهالر مع الأطفال الأصغر من 6 سنوات.</p><p dir="RTL">سيساعدك طبيبك (أو ممرضة الربو) على التعامل مع الربو لديك. وسيقومون بتعديل جرعة هذا الدواء إلى أقل جرعة تسمح بالسيطرة على الربو لديك. ومع ذلك، لا تعدل الجرعة أو توقفها دون التحدث إلى طبيبك (أو ممرضة الربو) أولاً.</p><p dir="RTL"><strong>استخدم مستنشقًا مسكّنًا منفصلاً لعلاج أعراض الربو عند حدوثها.</strong> احتفظ دائمًا بالمستنشق المسكّن معك لاستخدامه عند الحاجة. لا تستخدم سيمبيكورت توربوهالر لعلاج أعراض الربو - استخدم المستنشق المسكّن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب) استخدام سيمبيكورت توربوهالر كل يوم وعند الحاجة أيضًا (سيمبيكورت كعلاج مداومة وعلاج مسكّن)</strong></p><p dir="RTL">لا تستخدم سيمبيكورت توربوهالر على هذا النحو إلا إذا طلب منك طبيبك ذلك وإذا كان عمرك 12 عامًا أو أكثر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدم سيمبيكورت توربوهالر كل يوم. </strong>هذا يساعد على منع حدوث أعراض الربو. يمكنك أخذ:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>نشقة واحدة في الصباح<strong> و</strong>نشقة<strong> </strong>واحدة في المساء</p><p dir="RTL"><strong>أو</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نشقتين في الصباح</p><p dir="RTL">أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نشقتين في المساء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يُزيد طبيبك الجرعة إلى نشقتين مرتين يوميًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدم أيضًا سيمبيكورت توربوهالر كمستنشق مسكّن </strong>لعلاج أعراض الربو عند حدوثها، أو منع حدوثها (على سبيل المثال، عند ممارسة التمارين الرياضية أو عند التعرض لمسببات الحساسية) إذا تم الاتفاق مع طبيبك على ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهرت عليك أعراض الربو، فخذ نشقة واحدة وانتظر بضع دقائق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تشعر بتحسن، فخذ نشقة أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ أكثر من 6 نشقات في المرة الواحدة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">احتفظ دائمًا بسيمبيكورت توربوهالر معك، حتى تتمكن من استخدامه كمستنشق مسكّن عند الحاجة إليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اطلب المشورة الطبية العاجلة إذا لم يخفف سيمبيكورت توربوهالر من أعراض الربو لديك أو إذا تفاقمت أعراض الربو لديك على الرغم من تلقي العلاج بسيمبيكورت.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يلزم عادةً أخذ جرعة يومية إجمالية تزيد عن 8 نشقات. ومع ذلك، قد يسمح لك طبيبك بأخذ ما يصل إلى 12 نشقة يوميًا لفترة محدودة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تحتاج بانتظام إلى أخذ 8 نشقات أو أكثر يوميًا، فحدد موعدًا لزيارة طبيبك أو ممرضتك في أقرب وقت ممكن. فقد يضطران إلى تغيير علاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم أكثر من 12 نشقة في الإجمالي خلال 24 ساعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اطلب المشورة الطبية العاجلة إذا لم يخفف سيمبيكورت توربوهالر من أعراض الربو لديك أو إذا تفاقمت أعراض الربو لديك على الرغم من تلقي العلاج بسيمبيكورت.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يلزم عادةً أخذ جرعة يومية إجمالية تزيد عن 8 نشقات. ومع ذلك، قد يسمح لك طبيبك بأخذ ما يصل إلى 12 نشقة يوميًا لفترة محدودة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تحتاج بانتظام إلى أخذ 8 نشقات أو أكثر يوميًا، فحدد موعدًا لزيارة طبيبك أو ممرضتك في أقرب وقت ممكن. فقد يضطران إلى تغيير علاجك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تستخدم أكثر من 12 نشقة في الإجمالي خلال 24 ساعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مرض الانسداد الرئوي المزمن (COPD)</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يُستخدم فقط من قِبل البالغين (18 عامًا فما فوق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي نشقتان مرتين يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك طبيبك أيضًا أدوية موسع قصبي أخرى، على سبيل المثال مضادات الكولين (مثل تيوتروبيوم أو بروميد الإبراتروبيوم) لمرض الانسداد الرئوي المزمن لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحضير مستنشق سيمبيكورت توربوهالر الجديد</strong></p><p dir="RTL"><strong>قبل استخدام مستنشق سيمبيكورت توربوهالر الجديد</strong> <strong>للمرة الأولى</strong>، يجب عليك إعداده للاستخدام على النحو التالي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فك الغطاء وارفعه. قد تسمع صوت طقطقة.</p><p><img alt="" width="113" height="117" src="data:image/jpeg;base64,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" /></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك منشقة سيمبيكورت توربوهالر في وضع عمودي بحيث يكون المقبض الأحمر في الأسفل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدِر المقبض الأحمر إلى أبعد حد ممكن في اتجاه واحد. ثم أدره إلى أبعد حد ممكن في الاتجاه الآخر (يمكنك أن تبدأ التدوير من أي اتجاه). يجب أن تسمع صوت طقطقة. لا يهم ما إذا كانت النقرة تأتي في اللفة الأولى أو الثانية.</p><p><img alt="" width="113" height="120" src="data:image/jpeg;base64,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" /></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بذلك مرة أخرى، مع تدوير المقبض الأحمر في كلا الاتجاهين.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستنشق سيمبيكورت توربوهالر الآن معبأ وجاهز للاستخدام.</p><p dir="RTL"><strong>كيفية أخذ النشقات</strong></p><p dir="RTL">في كل مرة تحتاج فيها إلى أخذ نشقة، اتبع التعليمات أدناه.</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp; فك الغطاء وارفعه. قد تسمع صوت طقطقة.<strong><em> </em></strong></p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp; <strong>أمسك مستنشق سيمبيكورت توربوهالر في وضع عمودي </strong>بحيث يكون المقبض الأحمر في الأسفل.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp; لا تمسك الفوهة عند تعبئة مستنشق توربوهالر. لتعبئة مستنشق سيمبيكورت توربوهالر بالجرعات، أدر المقبض الأحمر إلى أقصى حد ممكن في اتجاه واحد. ثم أدره إلى أبعد حد ممكن في الاتجاه الآخر (يمكنك أن تبدأ التدوير من أي اتجاه). يجب أن تسمع صوت طقطقة. لا يهم ما إذا كانت النقرة تأتي في اللفة الأولى أو الثانية. تمت الآن تعبئة مستنشق توربوهالر وإعداده للاستخدام. لا تقم بتعبئة مستنشق سيمبيكورت توربوهالر إلا عند الحاجة لاستخدامه.</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أمسك سيمبيكورت توربوهالر بعيدًا عن فمك. أخرج الزفير برفق (بقدر ما يكون مريحًا). لا تزفر عبر سيمبيكورت توربوهالر.</p><p dir="RTL"><img alt="" width="113" height="120" src="data:image/jpeg;base64,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" /></p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp; ضع الفوهة برفق بين أسنانك. أغلق شفتيك. تنفس بعمق وبأقصى قوة ممكنة من خلال فمك. لا تقضم الفوهة أو تعض عليها.</p><p dir="RTL"><img alt="" width="113" height="119" src="data:image/jpeg;base64,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" /></p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخرج سيمبيكورت توربوهالر من فمك. ثم ازفر برفق.</strong> كمية الدواء التي يتم استنشاقها صغيرة جدًا. وهذا يعني أنك قد لا تتمكن من تذوقه بعد الاستنشاق. إذا كنت قد اتبعت التعليمات، فلا يزال بإمكانك أن تكون واثقًا من أنك قد استنشقت الجرعة وأن الدواء الآن في رئتيك.</p><p dir="RTL">7.&nbsp; إذا كنت ستأخذ نشقة ثانية، فكرر الخطوات من 2 إلى 6.</p><p dir="RTL">8.&nbsp;&nbsp;&nbsp;&nbsp; ضع الغطاء مرة أخرى بإحكام بعد الاستخدام.</p><p dir="RTL">9.&nbsp;&nbsp;&nbsp;&nbsp; اشطف فمك بالماء بعد أخذ جرعات الصباح و/أو المساء اليومية وابصق الماء.</p><p>&nbsp;</p><p>لا تحاول إزالة الفوهة أو لفها. فهي مثبتة بمنشقة سيمبيكورت توربوهالر ويجب عدم نزعها. لا تستخدم مستنشق سيمبيكورت توربوهالر إذا كانت تالفًا أو إذا انفصلت الفوهة عن سيمبيكورت توربوهالر.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">كما هو الحال مع جميع المستنشقات، يجب على مقدمي الرعاية التأكد من أن الأطفال الموصوف لهم سيمبيكورت توربوهالر يستخدمون أسلوب الاستنشاق الصحيح، كما هو موضح أعلاه.</p><p dir="RTL">&nbsp;</p><p>تنظيف مستنشق سيمبيكورت توربوهالر</p><p dir="RTL">امسح الجزء الخارجي من الفوهة مرة واحدة أسبوعيًا بمنديل جاف. لا تستخدم الماء أو السوائل.</p><p>&nbsp;</p><p>متى تبدأ في استخدام مستنشق جديد</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>يخبرك مؤشر الجرعة بعدد الجرعات (النشقات) المتبقية في سيمبيكورت توربوهالر، بدءًا من 30 أو 60 أو 120 جرعة عند امتلائه.</p><p dir="RTL"><img alt="" width="113" height="120" src="data:image/jpeg;base64,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" /></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>يحتوي مؤشر الجرعة على فواصل تبلغ 10 جرعات (للمستنشقات التي تحتوي على 60 و120 جرعة) وفواصل تبلغ 15 جرعة (للمستنشقات التي تحتوي على 30 جرعة). لذلك، لا يُظهر مؤشر الجرعة كل جرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما ترى علامة حمراء لأول مرة على حافة نافذة المؤشر، فهذا يعني أن هناك حوالي 20 جرعة متبقية. بالنسبة لآخر 10 جرعات، تكون خلفية مؤشر الجرعة حمراء. عند وصول علامة &quot;0&quot; الموجودة على الخلفية الحمراء إلى منتصف النافذة، يجب عليك البدء في استخدام مستنشق سيمبيكورت توربوهالر الجديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">ملاحظة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيظل المقبض يلف ويُصدر صوت &quot;نقرة&quot; حتى عندما يكون مستنشق سيمبيكورت توربوهالر فارغًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يصدر الصوت الذي تسمعه أثناء رج مستنشق سيمبيكورت توربوهالر بواسطة عامل تجفيف وليس الدواء. لذلك، لا يشير الصوت إلى كمية الدواء المتبقية في مستنشق سيمبيكورت توربوهالر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قمت بتعبئة مستنشق سيمبيكورت توربوهالر أكثر من مرة عن طريق الخطأ قبل أخذ جرعتك، فستظل تتلقى جرعة واحدة فقط. ومع ذلك، سيسجل مؤشر الجرعة جميع الجرعات التي تمت تبعئتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت جرعة من سيمبيكورت توربوهالر أكثر مما ينبغي</strong></p><p dir="RTL">من المهم أن تأخذ جرعتك كما هو موضح على ملصق الصيدلي أو كما يوصي طبيبك. يجب ألا تتجاوز الجرعة الموصوفة لك دون طلب المشورة الطبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الأكثر شيوعًا التي قد تحدث إذا أخذت جرعة من سيمبيكورت توربوهالر أكثر مما ينبغي هي الرعشة أو الصداع أو سرعة ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام سيمبيكورت توربوهالر</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت أخذ جرعة، فخذها بمجرد تذكرك لها. ومع ذلك، إذا اقترب موعد جرعتك التالية، فتخطى الجرعة الفائتة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تأخذ جرعة مضاعفة لتعويض جرعة فائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>ك</p><p dir="RTL"><strong>شائعة (قد تصيب شخصًا واحدًا على الأكثر من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان (الإحساس بنبض القلب)، أو الارتجاف، أو الارتعاش. إذا حدثت هذه الآثار، فإنها عادةً ما تكون خفيفة وتختفي عادةً مع استمرارك في استخدام سيمبيكورت توربوهالر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلاع الفموي (عدوى فطرية) في الفم. وهذا أقل احتمالاً أن يحدث إذا شطفت فمك بالماء بعد استخدام سيمبيكورت توربوهالر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب خفيف في الحلق، وسعال، وصوت أجش.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي (عدوى بالرئة) لدى مرضى الانسداد الرئوي المزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك بما إذا عانيت من أي مما يلي أثناء أخذ سيمبيكورت توربوهالر، فقد تكون أعراضًا لعدوى الرئة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو قشعريرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز المخاط، وتغير لونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السعال أو صعوبات التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> <strong>(قد تصيب شخصًا واحدًا من كل 100 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتململ أو العصبية أو الهياج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات في الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوّش الرؤية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تصيب شخصًا واحدًا على الأكثر من كل 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج قصبي (شد بالعضلات الموجودة في المسالك الهوائية يسبب أزيزًا). إذا حدث أزيز فجأة بعد استخدام سيمبيكورت توربوهالر، فتوقف عن استخدامه وتحدث إلى طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا (قد تصيب شخصًا واحدًا على الأكثر من كل 10000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في السلوك، خاصةً لدى الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضيق في الصدر (ذبحة صدرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة كمية السكر (الجلوكوز) في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في التذوق، مثل مذاق غير لذيذ في الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في ضغط الدم لديك.</p><p dir="RTL">يمكن أن تؤثر الكورتيكوستيرويدات المستنشقة على الإنتاج الطبيعي للهرمونات الستيرويدية في جسمك، خاصةً إذا استخدمت جرعات عالية لفترة طويلة. تشمل الآثار:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كثافة المعادن في العظام (ترقق العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعتام عدسة العين (كاتاراكت).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الزرق (زيادة الضغط في العين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ معدل نمو الأطفال والمراهقين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثير على الغدة الكظرية (غدة صغيرة موجودة بجوار الكلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تقل احتمالية حدوث هذه الآثار مع الكورتيكوستيرويدات المستنشقة مقارنةً بأقراص الكورتيكوستيرويدات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدواء بعيدًا عن متناول أيدي الأطفال ونظرهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على العبوة الكرتونية أو على ملصق المستنشق بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يتطلب هذا الدواء أي شروط تخزين خاصة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستعملها. هذه التدابير من شأنها حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة هي بوديسونيد وفورموتيرول فومارات ثنائي الهيدرات. تحتوي كل جرعة مستنشقة على 160 مكغ من البوديسونيد و4.5 ميكروغرامات من فورموتيرول فومارات ثنائي الهيدرات، وهذا يعادل جرعة مقننة تبلغ 200 مكغ من بوديسونيد و6 مكغ من فورموتيرول فومارات ثنائي الهيدرات.</p><p dir="RTL">المكون الآخر هو أحادي هيدرات اللاكتوز (الذي يحتوي على بروتينات الحليب).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيمبيكورت توربوهالر&nbsp; هو مستنشق يحتوي على دوائك. مسحوق الاستنشاق أبيض اللون. يحتوي كل مستنشق إما على 60 أو 120 جرعة وله جسم أبيض مع مقبض دوار أحمر. يحتوي المقبض الدوار على رمز برايل يحمل الرقم 6 لتمييزه عن منتجات AstraZeneca الأخرى المستنشقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيمبيكورت توربوهالر متوفر في عبوة بها مستنشق واحد يحتوي على 120 جرعة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">AstraZeneca AB</p><p dir="RTL">SE-151 85 S&ouml;dert&auml;lje</p><p dir="RTL">السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL"><strong>&nbsp;</strong>AstraZeneca AB</p><p dir="RTL">Forskargatan 18</p><p dir="RTL">SE-151 36 S&ouml;dert&auml;lje</p><p dir="RTL">السويد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Symbicort Turbuhaler, 160 micrograms/4.5 micrograms/inhalation, inhalation powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide
160 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation.
Each metered dose contains: budesonide 200 micrograms/inhalation and formoterol fumarate dihydrate 6 micrograms/inhalation.
Excipient with known effect: Lactose monohydrate 730 micrograms per delivered dose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder. 
White powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Asthma</strong></p><p>Symbicort Turbohaler is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting &beta;<sub>2</sub> adrenoceptor agonist) is appropriate:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting &beta;<sub>2</sub> adrenoceptor agonists.</p><p>or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients already adequately controlled on both inhaled corticosteroids and long‑acting &beta;<sub>2</sub> adrenoceptor agonists.</p><p><strong>Chronic Obstructive Pulmonary Disease (COPD)</strong></p><p>Symbicort Turbohaler is indicated in adults, aged 18&nbsp;years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in&nbsp;1 second (FEV<sub>1</sub>) &lt;70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: For inhalation use.</p><p><u>Posology</u></p><p><strong>Asthma</strong></p><p>The dosage of the components of Symbicort is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the maintenance dose is adjusted. It is recommended that all patients with asthma are provided with a written personal asthma action plan. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of &beta;<sub>2</sub> adrenoceptor agonists and/or corticosteroids by individual inhalers should be prescribed.</p><p>The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be regularly reassessed by their prescriber/health care provider so that the usage of Symbicort remains optimal. When a new treatment is initiated or treatment dose adjusted, patients should be assessed more frequently.</p><p>For Symbicort there are two treatment approaches:</p><p><strong>A.&nbsp; Symbicort maintenance therapy: </strong>Symbicort is taken as regular maintenance treatment with a separate rapid-acting bronchodilator as rescue.</p><p><strong>B.&nbsp; Symbicort maintenance and reliever therapy: </strong>Symbicort is taken as regular maintenance treatment and as needed in response to symptoms.</p><p>&nbsp;</p><p><strong><u>A. Symbicort maintenance therapy</u></strong><br />Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.</p><p><em>Recommended doses:</em></p><p><em>Adults (18&nbsp;years and older):</em><strong> </strong>1-2 inhalations twice daily. Some patients may require up to a maximum of 4&nbsp;inhalations twice daily.</p><p><em>Adolescents (12 &ndash; 17</em>&nbsp;<em>years):</em><strong> </strong>1-2&nbsp;inhalations twice daily.</p><p>In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include Symbicort given once daily, when in the opinion of the prescriber, a long-acting bronchodilator in combination with an inhaled corticosteroid would be required to maintain control.</p><p>Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy.</p><p><em>Children (6&nbsp;years and older):</em> A lower strength (100&nbsp;micrograms/6&nbsp;micrograms/inhalation) is available for children 6-11&nbsp;years.</p><p><em>Children under 6&nbsp;years:</em> As only limited data are available, Symbicort is not recommended for children younger than 6&nbsp;years.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>B. Symbicort maintenance and reliever therapy</u></strong><br />Patients take a daily maintenance dose of Symbicort and in addition take Symbicort as needed in response to symptoms. Patients should be advised to always have Symbicort available for rescue use.</p><p>&nbsp;</p><p>For patients taking Symbicort as reliever, preventative use of Symbicort for allergen-or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.</p><p>&nbsp;</p><p>Symbicort maintenance and reliever therapy should especially be considered for patients with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inadequate asthma control and in frequent need of reliever medication</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma exacerbations in the past requiring medical intervention</p><p>&nbsp;</p><p>Close monitoring for dose-related adverse effects is needed in patients who frequently take high numbers of Symbicort as-needed inhalations.</p><p><em>Recommended doses:<br />Adults and adolescents (12&nbsp;years and older):<strong> </strong></em>The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2&nbsp;inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.<strong><em> </em></strong></p><p>A total daily dose of more than 8&nbsp;inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8&nbsp;inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.</p><p><em>Children under 12&nbsp;years:</em> Symbicort maintenance and reliever therapy is not recommended for children.</p><p><strong>COPD</strong></p><p><em>Recommended doses:</em></p><p><em>Adults:</em><strong> </strong>2&nbsp;inhalations twice daily</p><p><strong>General information</strong></p><p><em>Special patient groups:</em><strong> </strong><br />There are no special dosing requirements for elderly patients. There are no data available for use of Symbicort in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><em>Instructions for correct use of Symbicort Turbohaler:</em></p><p>The inhaler is inspiratory flow-driven, which means that when the patient inhales through the mouthpiece, the substance will follow the inspired air into the airways.</p><p><strong>Note:</strong> It is important to instruct the patient</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; to carefully read the instructions for use in the patient information leaflet which is packed together with each Symbicort Turbohaler Inhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; to breathe in forcefully and deeply through the mouthpiece to ensure that an optimal dose is delivered to the lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; never to breathe out through the mouthpiece.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; to replace the cover of the Symbicort Turbohaler inhaler after use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; to rinse their mouth out with water after inhaling the maintenance dose to minimise the risk of oropharyngeal thrush. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.</p><p>The patient may not taste or feel any medication when using Symbicort Turbohaler inhaler due to the small amount of drug dispensed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity (allergy) to budesonide, formoterol or lactose (which contains small amounts of milk proteins).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dosing advice</u></p><p>Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Symbicort. Regular review of patients as treatment is stepped down is important. The lowest effective dose of Symbicort should be used (see section 4.2).</p><p>&nbsp;</p><p>Patients should be advised to have their rescue inhaler available at all times, either a separate rapid-acting bronchodilator (for all patients using Symbicort as maintenance therapy only (therapy A)) or Symbicort (for asthma patients using Symbicort as maintenance and reliever therapy (therapy B).</p><p>If patients take Symbicort as maintenance (therapy A or B), they should be reminded to take their Symbicort maintenance dose as prescribed, even when asymptomatic.</p><p>&nbsp;</p><p>To minimise the risk of oropharyngeal candida infection (see section 4.8), the patient should be instructed to rinse their mouth out with water after inhaling the maintenance dose. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.</p><p>&nbsp;</p><p>It is recommended that the maintenance dose is tapered when the treatment is discontinued and the dosing should not be stopped abruptly. Complete withdrawal of inhaled corticosteroids should not be considered unless it is temporarily required to confirm diagnosis of asthma.</p><p><u>&nbsp;</u></p><p><u>Deterioration of disease</u></p><p>Serious asthma-related adverse events and exacerbations may occur during treatment with Symbicort. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with Symbicort.</p><p>If patients find the treatment less effective, or need more inhalations than usual, medical attention must be sought (see section&nbsp;4.2). Sudden and progressive deterioration in control of asthma or COPD is potentially life threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.</p><p>Patients should not be initiated on Symbicort during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.</p><p><u>Transfer from oral therapy</u></p><p>If there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy, care should be taken when transferring patients to Symbicort therapy.</p><p>The benefits of inhaled budesonide therapy would normally minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Recovery may take a considerable amount of time after cessation of oral steroid therapy and hence oral steroid‑dependent patients transferred to inhaled budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances HPA axis function should be monitored regularly.</p><p><!--[if supportFields]><s><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span></s><![endif]--><!--[if supportFields]><s><span
lang=EN-GB><span style='mso-element:field-end'></span></span></s><![endif]--></p><p>During transfer from oral therapy to Symbicort, a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases, a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary.</p><p><u>Excipients</u></p><p>Symbicort Turbohaler contains lactose monohydrate (&lt;1&nbsp;mg/inhalation). This amount does not normally cause problems in lactose intolerant people. The excipient lactose contains small amounts of milk proteins, which may cause allergic reactions.</p><p><u>Interactions with other medicinal products</u></p><p>Concomitant treatment with itraconazole, ritonavir or other potent CYP3A4 inhibitors should be avoided (see section&nbsp;4.5). If this is not possible the time interval between administration of the interacting drugs should be as long as possible. In patients using potent CYP3A4 inhibitors, Symbicort maintenance and reliever therapy is not recommended.</p><p><u>Caution with special diseases</u></p><p>Symbicort should be administered with caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.</p><p>Caution should be observed when treating patients with prolongation of the QTc-interval. Formoterol itself may induce prolongation of the QTc-interval.</p><p>Potentially serious hypokalaemia may result from high doses of &beta;<sub>2</sub> adrenoceptor agonists. Concomitant treatment of &beta;<sub>2</sub> adrenoceptor agonists with drugs which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the &beta;<sub>2</sub> adrenoceptor agonist. Particular caution is recommended in unstable asthma with variable use of rescue bronchodilators, in acute severe asthma as the associated risk may be augmented by hypoxia and in other conditions when the likelihood for hypokalaemia is increased. It is recommended that serum potassium levels are monitored during these circumstances.</p><p>As for all &beta;<sub>2</sub> adrenoceptor agonists, additional blood glucose controls should be considered in diabetic patients.</p><p>The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.</p><p>&nbsp;</p><p><u>Systemic effects</u></p><p>Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhalation treatment than with oral corticosteroids. Possible systemic effects include Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see section 4.8).</p><p>Potential effects on bone density should be considered particularly in patients on high doses for prolonged periods that have coexisting risk factors for osteoporosis. Long-term studies with inhaled budesonide in children at mean daily doses of 400&nbsp;micrograms (metered dose) or in adults at daily doses of 800&nbsp;micrograms (metered dose) have not shown any significant effects on bone mineral density. No information regarding the effect of Symbicort at higher doses is available.</p><p>Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported after use of systemic and topical corticosteroids.</p><p>&nbsp;</p><p><u>Adrenal function</u></p><p>Treatment with supplementary systemic steroids or inhaled budesonide should not be stopped abruptly.</p><p>The prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may also result in clinically significant adrenal suppression. Therefore, additional systemic corticosteroid cover should be considered during periods of stress such as severe infections or elective surgery. Rapid reduction in the dose of steroids can induce acute adrenal crisis. Symptoms and signs which might be seen in acute adrenal crisis may be somewhat vague but may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, seizures, hypotension and hypoglycaemia.</p><p>&nbsp;</p><p><u>Paradoxical bronchospasm</u></p><p>As with other inhalation therapy, paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath, after dosing. If the patient experiences paradoxical bronchospasm Symbicort should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway (see section 4.8).</p><p><u>Paediatric population</u></p><p>It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be re-evaluated with the aim of reducing the dose of inhaled corticosteroid to the lowest dose at which effective control of asthma is maintained, if possible. The benefits of the corticosteroid therapy and the possible risks of growth suppression must be carefully weighed. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.</p><p>Limited data from long-term studies suggest that most children and adolescents treated with inhaled budesonide will ultimately achieve their adult target height. However, an initial small but transient reduction in growth (approximately 1&nbsp;cm) has been observed. This generally occurs within the first year of treatment.</p><p><u>COPD population</u></p><p>There are no clinical study data on Symbicort Turbohaler available in COPD patients with a pre-bronchodilator FEV<sub>1</sub> &gt;50% predicted normal and with a post-bronchodilator FEV<sub>1</sub> &lt;70% predicted normal (see section 5.1).</p><p>&nbsp;</p><p>An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.</p><p>&nbsp;</p><p>There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.</p><p>Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.</p><p>Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacokinetic interactions</em></p><p>Potent inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors) are likely to markedly increase plasma levels of budesonide and concomitant use should be avoided. If this is not possible the time interval between administration of the inhibitor and budesonide should be as long as possible (section&nbsp;4.4). In patients using potent CYP3A4 inhibitors, Symbicort maintenance and reliever therapy is not recommended.</p><p>&nbsp;</p><p>The potent CYP3A4 inhibitor ketoconazole, 200&nbsp;mg once daily, increased plasma levels of concomitantly orally administered budesonide (single dose of 3&nbsp;mg) on average six-fold. When ketoconazole was administered 12&nbsp;hours after budesonide the concentration was on average increased only three-fold showing that separation of the administration times can reduce the increase in plasma levels. Limited data about this interaction for high-dose inhaled budesonide indicates that marked increase in plasma levels (on average four-fold) may occur if itraconazole, 200&nbsp;mg once daily, is administered concomitantly with inhaled budesonide (single dose of 1000&nbsp;&mu;g).</p><p><em>Pharmacodynamic interactions</em></p><p>Beta-adrenergic blockers can weaken or inhibit the effect of formoterol. Symbicort should therefore not be given together with beta-adrenergic blockers (including eye drops) unless there are compelling reasons.</p><p>Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias.</p><p>In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards &beta;<sub>2</sub> sympathomimetics.</p><p>Concomitant treatment with monoamine oxidase inhibitors, including agents with similar properties such as furazolidone and procarbazine, may precipitate hypertensive reactions.</p><p>There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.</p><p>Concomitant use of other beta-adrenergic drugs or anticholinergic drugs can have a potentially additive bronchodilating effect.</p><p>Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.</p><p>Hypokalaemia may result from &beta;<sub>2</sub>-agonist therapy and may be potentiated by concomitant treatment with xanthine derivatives, corticosteroids and diuretics (see section&nbsp;4.4).</p><p>Budesonide and formoterol have not been observed to interact with any other drugs used in the treatment of asthma.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For Symbicort or the concomitant treatment with formoterol and budesonide, no clinical data on exposed pregnancies are available. Data from an embryo-foetal development study in the rat, showed no evidence of any additional effect from the combination.</p><p>There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse effects in reproduction studies at very high systemic exposure levels (see section&nbsp;5.3).</p><p>Data on approximately 2000&nbsp;exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations (see section&nbsp;5.3). This is not likely to be relevant for humans given recommended doses.</p><p>Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risks for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.</p><p>During pregnancy, Symbicort should only be used when the benefits outweigh the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.</p><p><u>Breastfeeding</u></p><p>Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the suckling child are anticipated. It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of Symbicort to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.</p><p><u>Fertility</u></p><p>There is no data available on the potential effect of budesonide on fertility. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure (see section&nbsp;5.3).<!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symbicort has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Symbicort contains both budesonide and formoterol, the same pattern of undesirable effects as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side effects of &beta;<sub>2</sub> adrenoceptor agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment.</p><p>Adverse reactions, which have been associated with budesonide or formoterol, are given below, listed by system organ class and frequency. Frequencies are defined as: very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1000 to &lt;1/100), rare (&sup3;1/10 000 to &lt;1/1000) and very rare (&lt;1/10 000).</p><p><strong>Table 1</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p><u>SOC</u></p></td><td style="vertical-align:top"><p><strong><u>Frequency</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Adverse Drug Reaction</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Candida infections in the oropharynx Pneumonia (in COPD patients)</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cushing&rsquo;s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Aggression, psychomotor hyperactivity, anxiety, sleep disorders</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Depression, behavioural changes (predominantly in children)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache, tremor</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Taste disturbances</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vision blurred (see also section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cataract and glaucoma</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angina pectoris. Prolongation of QTc‑interval</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Variations in blood pressure</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Mild irritation in the throat, coughing, dysphonia including hoarseness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Bruises</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Muscle cramps</p></td></tr></tbody></table><p>&nbsp;</p><p>Candida infection in the oropharynx is due to drug deposition. Advising the patient to rinse the mouth out with water after each maintenance dose will minimise the risk. Oropharyngeal Candida infection usually responds to topical anti-fungal treatment without the need to discontinue the inhaled corticosteroid. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.</p><p>As with other inhalation therapy, paradoxical bronchospasm may occur very rarely, affecting less than 1 in 10,000 people, with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway. Symbicort should be discontinued immediately, the patient should be assessed and an alternative therapy instituted if necessary (see section&nbsp;4.4).</p><p>Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur. Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity.</p><p>Treatment with &beta;<sub>2</sub> adrenoceptor agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.</p><p><u>Paediatric population</u></p><p>It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored (see section&nbsp;4.4).</p><p>To report any side effect(s):</p><ul><li><strong><em>Saudi Arabia: </em></strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Other GCC States:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if supportFields]><span lang=EN-GB><span
style='mso-element:field-begin'></span><span style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]-->An overdose of formoterol would likely lead to effects that are typical for &beta;<sub>2</sub> adrenoceptor agonists: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc-interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment may be indicated. A dose of 90 micrograms administered during three hours in patients with acute bronchial obstruction raised no safety concerns.</p><p>Acute overdosage with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects, such as hypercorticism and adrenal suppression, may appear.</p><p>If Symbicort therapy has to be withdrawn due to overdose of the formoterol component of the drug, provision of appropriate inhaled corticosteroid therapy must be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases: Adrenergics, Inhalants.</p><p>ATC-code: <!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]-->R03AK07</p><p><u>Mechanisms of action and Pharmacodynamic effects</u></p><p>Symbicort contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used either as maintenance and reliever therapy or as maintenance treatment of asthma.</p><p><em>Budesonide</em></p><p>Budesonide is a glucocorticosteroid which when inhaled has a dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse effects than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.</p><p><em>Formoterol</em></p><p>Formoterol is a selective &beta;<sub>2</sub> adrenoceptor agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose-dependent, with an onset of effect within 1-3 minutes. The duration of effect is at least 12 hours after a single dose.</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><strong>Asthma</strong></p><p><em><u>Budesonide/formoterol</u></em><u> <em>maintenance therapy (Therapy A in Section 4.2)</em></u><br />Clinical studies in adults have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations. In two 12-week studies the effect on lung function of budesonide/formoterol was equal to that of the free combination of budesonide and formoterol, and exceeded that of budesonide alone. All treatment arms used a short-acting &beta;<sub>2</sub> adrenoceptor agonist (SABA) as needed. There was no sign of attenuation of the anti-asthmatic effect over time.</p><p>Two 12-week paediatric studies have been performed in which 265&nbsp;children aged 6-11&nbsp;years were treated with a maintenance dose of budesonide/formoterol (2&nbsp;inhalations of 80&nbsp;micrograms&nbsp;/4.5&nbsp;micrograms/inhalation twice daily), and a SABA as needed. In both studies, lung function was improved and the treatment was well tolerated compared to the corresponding dose of budesonide alone.</p><p><em><u>Budesonide/formoterol maintenance and reliever therapy (Therapy B in Section 4.2)</u></em><br />A total of 12076 asthma patients were included in 5 double-blind efficacy and safety studies (4447&nbsp;were randomised to budesonide/formoterol maintenance and reliever therapy) for 6 or 12 months. Patients were required to be symptomatic despite use of inhaled glucocorticosteroids.</p><p>Budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations for all comparisons in all 5&nbsp;studies. This included a comparison with budesonide/formoterol at a higher maintenance dose with terbutaline as reliever (study&nbsp;735) and budesonide/formoterol at the same maintenance dose with either formoterol or terbutaline as reliever (study&nbsp;734) (Table&nbsp;2). In study&nbsp;735, lung function, symptom control, and reliever use were similar in all treatment groups. In study&nbsp;734, symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments. In the 5&nbsp;studies combined, patients receiving budesonide/formoterol maintenance and reliever therapy used, on average, no reliever inhalations on 57% of treatment days. There was no sign of development of tolerance over time.</p><p>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overview of severe exacerbations in clinical studies (budesonide/formoterol maintenance and reliever therapy)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><thead><tr><td rowspan="2" style="vertical-align:top"><p>Study No. Duration</p></td><td rowspan="2" style="vertical-align:top"><p>Treatment groups</p></td><td rowspan="2" style="vertical-align:top"><p>n</p></td><td colspan="2" style="vertical-align:top"><p>Severe exacerbations<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Events</p></td><td style="vertical-align:top"><p>Events/ patient-year</p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Study&nbsp;735<br />6 months</strong></p></td><td style="vertical-align:top"><p><strong>Budesonide/formoterol</strong><strong> 160/4.5 &micro;g bd + as needed </strong></p></td><td style="vertical-align:top"><p><strong>1103</strong></p></td><td style="vertical-align:top"><p><strong>125</strong></p></td><td style="vertical-align:top"><p><strong>0.23</strong><sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Budesonide/formoterol 320/9 &micro;g bd + terbutaline 0.4 mg as needed</p></td><td style="vertical-align:top"><p>1099</p></td><td style="vertical-align:top"><p>173</p></td><td style="vertical-align:top"><p>0.32<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol/fluticasone 2 x 25/125 &micro;g bd + terbutaline 0.4 mg as needed</p></td><td style="vertical-align:top"><p>1119</p></td><td style="vertical-align:top"><p>208</p></td><td style="vertical-align:top"><p>0.38<sup> </sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Study&nbsp;734<br />12 months </strong></p></td><td style="vertical-align:top"><p><strong>Budesonide/formoterol</strong><strong> 160/4.5 &micro;g bd + as needed</strong></p></td><td style="vertical-align:top"><p><strong>1107</strong></p></td><td style="vertical-align:top"><p><strong>194</strong></p></td><td style="vertical-align:top"><p><strong>0.19</strong><sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Budesonide/formoterol 160/4.5 &micro;g bd + formoterol 4.5 &micro;g as needed</p></td><td style="vertical-align:top"><p>1137</p></td><td style="vertical-align:top"><p>296</p></td><td style="vertical-align:top"><p>0.29<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p>Budesonide/formoterol 160/4.5 &micro;g bd + terbutaline 0.4 mg as needed</p></td><td style="vertical-align:top"><p>1138</p></td><td style="vertical-align:top"><p>377</p></td><td style="vertical-align:top"><p>0.37</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospitalisation/emergency room treatment or treatment with oral steroids</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in exacerbation rate is statistically significant (P value &lt;0.01) for both comparisons</p><p>&nbsp;</p><p>Comparable efficacy and safety in adolescents and adults were demonstrated in 6 double-blind studies, comprising the 5 studies mentioned above and an additional study using a higher maintenance dose of 160/4.5 micrograms, two inhalations twice daily. These assessments were based on a total of 14385 asthma patients of whom 1847 were adolescents. The number of adolescent patients taking more than 8 inhalations on at least one day as part of budesonide/formoterol maintenance and reliever therapy was limited, and such use was infrequent.</p><p><br />In 2 other studies with patients seeking medical attention due to acute asthma symptoms, budesonide/formoterol provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.</p><p>&nbsp;</p><p><strong>COPD</strong></p><p>In two 12-month studies, the effect on lung function and the rate of exacerbation (defined as courses of oral steroids and/or course of antibiotics and/or hospitalisations) in patients with moderate to severe COPD was evaluated. The inclusion criteria for both studies was pre-bronchodilator FEV<sub>1</sub> &lt;50% predicted normal. Median post-bronchodilator FEV<sub>1</sub> at inclusion in the trials was 42% predicted normal.</p><p>The mean number of exacerbations per year (as defined above) was significantly reduced with budesonide/formoterol as compared with treatment with formoterol alone or placebo (mean rate 1.4 compared with 1.8-1.9 in the placebo/formoterol group). The mean number of days on oral corticosteroids/patient during the 12&nbsp;months was slightly reduced in the budesonide/formoterol group (7-8&nbsp;days/patient/year compared with 11-12 and 9-12&nbsp;days in the placebo and formoterol groups, respectively). For changes in lung-function parameters, such as FEV<sub>1, </sub>budesonide/formoterol was not superior to treatment with formoterol alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if supportFields]><u><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span></u><![endif]--><!--[if supportFields]><u><span
lang=EN-GB><span style='mso-element:field-end'></span></span></u><![endif]--><!--[if supportFields]><u><span
lang=EN-GB><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'>  </span></span></u><![endif]--><!--[if supportFields]><u><span
lang=EN-GB><span style='mso-element:field-end'></span></span></u><![endif]--><u>Absorption</u></p><p>The fixed‑dose combination of budesonide and formoterol, and the corresponding monoproducts have been shown to be bioequivalent with regard to systemic exposure of budesonide and formoterol, respectively. In spite of this, a small increase in cortisol suppression was seen after administration of the fixed‑dose combination compared to the monoproducts. The difference is considered not to have an impact on clinical safety.</p><p>There was no evidence of pharmacokinetic interactions between budesonide and formoterol.</p><p>Pharmacokinetic parameters for the respective substances were comparable after the administration of budesonide and formoterol as monoproducts or as the fixed‑dose combination. For budesonide, AUC was slightly higher, rate of absorption more rapid and maximal plasma concentration higher after administration of the fixed combination. For formoterol, maximal plasma concentration was similar after administration of the fixed combination. Inhaled budesonide is rapidly absorbed and the maximum plasma concentration is reached within 30&nbsp;minutes after inhalation. In studies, mean lung deposition of budesonide after inhalation via the powder inhaler ranged from 32% to 44% of the delivered dose. The systemic bioavailability is approximately 49% of the delivered dose. In children 6‑16&nbsp;years of age the lung deposition falls in the same range as in adults for the same given dose. The resulting plasma concentrations were not determined.</p><p>Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10&nbsp;minutes after inhalation. In studies the mean lung deposition of formoterol after inhalation via the powder inhaler ranged from 28% to 49% of the delivered dose. The systemic bioavailability is about 61% of the delivered dose.</p><p><u>Distribution and biotransformation</u></p><p>Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 l/kg for formoterol and 3 l/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6-beta-hydroxy-budesonide and 16-alfa-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.</p><p><u>Elimination</u></p><p>The major part of a dose of formoterol is transformed by liver metabolism followed by renal elimination. After inhalation, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 l/min) and the terminal elimination half-life averages 17&nbsp;hours.</p><p>Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are eliminated in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 l/min) and the plasma elimination half-life after i.v. dosing averages 4&nbsp;hours.</p><p>The pharmacokinetics of budesonide or formoterol in patients with renal failure are unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.</p><p><u>Linearity/non-linearity</u></p><p>Systemic exposure for both budesonide and formoterol correlates in a linear fashion to administered dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxicity observed in animal studies with budesonide and formoterol, given in combination or separately, were effects associated with exaggerated pharmacological activity.</p><p>In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if supportFields]><span lang=EN-GB><span
style='mso-element:field-begin'></span><span style='mso-spacerun:yes'>  </span></span><![endif]--><!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]-->Lactose monohydrate (which contains milk proteins).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30<sup>o</sup>C. Keep the container tightly closed, in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symbicort Turbuhaler is an inspiratory flow driven, multidose powder inhaler. The inhaler is white with a red turning grip. The inhaler is made of different plastic materials (PP, PC, HDPE, LDPE, LLDPE, PBT). In each secondary package there is 1inhaler containing<br />120 doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB 151 85 Södertälje Sweden
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>